# British Journal of Cancer

## EDITORIAL BOARD

<table>
<thead>
<tr>
<th>Editor</th>
<th>Chairman</th>
<th>Clinical Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.R. Twentyman</td>
<td>D.G. Harnden</td>
<td>P.J. Selby</td>
</tr>
<tr>
<td>Cambridge</td>
<td>Manchester</td>
<td>Leeds</td>
</tr>
</tbody>
</table>

G.E. Adams – Didcot, Oxon  
P. Alexander – Southampton  
K.D. Bagshawe – London  
M. Baum – London  
C.C. Bird – Edinburgh  
D.T. Bishop – Leeds  
N.M. Bleeheen – Cambridge  
P. Boyle – Lyon  
D.N. Carney – Dublin  
C.E.D. Chilvers – Nottingham  
F.J. Cleton – Leiden  
T.A. Connors – Sutton  
D. Crowther – Manchester  
G.A. Currie – Oxted, Surrey  
J. Denekamp – Northwood  
M. D’Incalci – Milan  
M.J. Embleton – Nottingham  
P. Gallimore – Birmingham  
C.F. Graham – Oxford  
J.D. Hardcastle – Nottingham  
K.R. Harrap – Sutton  
A.L. Harris – Oxford  
D. Heath – Birmingham  
J. Hickman – Manchester  
A. Horwich – Sutton  
D.K. Hossfeld – Hamburg  
A. Howell – Manchester  

<table>
<thead>
<tr>
<th>Clinical Editor</th>
</tr>
</thead>
</table>
| B. Ketterer – London  
L.J. Kinlen – Edinburgh  
R.C.F. Leonard – Edinburgh  
J.O’D. McGee – Oxford  
J.G. McVie – London  
J. Malpas – London  
C. Marshall – London  
D. Metcalf – Melbourne  
N.A. Mitchison – London  
M. Moore – Slough  
T.J. Perren – Leeds  
B. Ponder – Cambridge  
J. Pritchard – London  
T.J. Priestman – Birmingham  
R.L. Souhami – London  
I.F. Tannock – Toronto  
G.M. Taylor – Manchester  
J.M. Trent – Ann Arbor  
V. Van Heyningen – Edinburgh  
M.P. Vessey – Oxford  
N.J. Wald – London  
P. Wardman – Northwood  
R.A. Weiss – London  
N.M. Wilkie – Glasgow  
R.C.N. Williamson – London  
P. Workman – Glasgow  
J.A. Wyke – Glasgow

<table>
<thead>
<tr>
<th>Editorial Assistants</th>
</tr>
</thead>
</table>
| Janice Baiton – Cambridge  
Diane Roberts – Leeds |
Aredia
pamidronate disodium

for the treatment of tumour-induced hypercalcaemia

- Reliable response
  "Calcium concentration fell in all patients [n=30] and was restored to normal in all but two"\(^1\)

- Sustained effectiveness
  Normocalcaemia maintained for an average of 3 weeks\(^1\)

- Well tolerated
  Reported side-effects not of clinical relevance\(^{1,2}\)

- Effective as a single infusion

**Prescribing Notes**
- Aredia\(^\text{®}\) (pamidronate disodium)
- Presentation: Ampoules of 5ml aqueous injectable concentrate containing 15mg pamidronate disodium (calculated as the anhydrous form) for intravenous infusion.
- Indication: Tumour-induced hypercalcaemia.
- Dosage: Adults and elderly: Depending on the initial calcium plasma level, 15-90mg by slow intravenous infusion in sodium chloride 0.9%. Infusion rate should not exceed 30mg/2hrs, and concentration should not exceed 30mg/250ml. Total dose can be given either as a single i.v. infusion or divided over 2-4 consecutive days. Rehydration with normal saline before treatment is recommended. Not recommended for children. See full prescribing information.
- Contraindications: Known hypersensitivity to pamidronate disodium or other bisphosphonates.
- Precautions: Monitor clinical and biochemical effects. Do not administer as a bolus injection. Do not co-administer with other bisphosphonates, plicamycin (mithramycin) or calcium containing infusion solutions. Caution in patients with severe renal insufficiency (multiple dosing recommended).
- Side-effects: Asymptomatic hypercalcaemia and transient pyrexia.
- Occasionally transient lymphocytopenia and hypomagnesaemia. Less frequently reactions at infusion sites and gastrointestinal effects. For further information see full prescribing information.

**Packs**
GASTROINTESTINAL CANCER

29–30 November 1991

Venue: The Royal College of Radiologists, London

TOPICS:
The Investigation, Management, Radiotherapy and Surgical Treatments available for Carcinoma of the Oesophagus, Stomach, Gastrointestinal Tract, Rectum, Colorectal and Anal Canal

SPEAKERS:
Dr S. Arnott, London
Dr E. Bessel, Nottingham
Dr H. Close, Leeds
Mr R. Earlam, London
Mr J. Fielding, Birmingham
Dr J. Gerard, Lyon
Dr G. Howard, Edinburgh

Dr R. James, Manchester
Mr S. Leveson, York
Dr I. Talbot, London
Dr A. Timothy, London
Dr D. Wynick, London
Dr G. Vaughan-Hudson, London
Professor N. Williams, London

Registration Fee: £110.00 (inc. Lunch)

Further details from:
The Conference Office
The Royal College of Radiologists
38 Portland Place
London W1N 3DG
U.K.

Tel: (071) 636 4432
Fax: (071) 323 3100
Editorial Announcement

This issue of the British Journal of Cancer contains a revised version of the ‘Notice to Contributors’.

The changes from the previous version are mainly clarifications of existing instructions. The format for ‘Short Communications’ has however been substantially revised. We now ask that such papers contain the usual section headings plus a short summary of around 50 words. This will make it possible for summaries to be included in computer databases.

There are two changes in the format for references. We now require that the names of all authors are given in the reference list, even when there are more than 6 authors. In addition, the first and last page numbers of all referenced papers and book chapters are to be given.

In accordance with the practise of almost all other biomedical journals we now find it necessary to charge authors for all colour illustrations and this is now pointed out in the ‘Notice to Contributors’.
2nd INTERNATIONAL CONGRESS ON ORAL CANCER

2–5 December, 1991
New Delhi, India

Organising Secretary

Mrs Arati Walia
2nd ICOOC
B-4, South Extension, Part-II
New Delhi – 110049, India

Tel: 646 2354
Telex: 031-66956 AKAS-IN,
Fax: 91-11-6444966
The world’s most intensively cited leukemia journal, now published by Macmillan

LEUKEMIA

EDITORS
C. Nicole Muller-Berat, Denmark
William M. Crist, USA Edward S. Henderson, USA
Mel F. Greaves, UK

CLINICAL STUDIES
CELL BIOLOGY
MOLECULAR HEMATOLOGY
- Differentiation
- In Vitro Models
- Molecular Pharmacology
- Membrane Markers
- Oncogenes
- Gene Therapy
- Enzymatic Markers
- Stem Cells
- Virology
- Biological Modifiers
- Bone Marrow Transplantation
- Therapeutic Trials
- Cell Cycle
- Growth Factors
- Chromosomes

FROM RECENT ISSUES OF LEUKEMIA

OPEN FORUM:
Remarkably Long Survival of a Patient with Ph-Positive Chronic Myeloid Leukemia and 5' bcr Rearrangement

Cure of Acute Myelocytic Leukemia in Adults: A Reality R.B. Geller, R. Saral, J.E. Karp, G.W. Santos & P.J. Burke

CONGRESS LETTER:
Chronic Myelogenous Leukemia — The Unfolding Saga
J.M. Goldman, G. Groswold, D. Baltimore & R.P. Gale

COMMENTS:
The Sellsafford Childhood Leukemia Cluster: Are Germline Mutations Responsible? M.F. Greaves

ORIGINAL ARTICLES:
Induction of Genes for Transcription Factors by normal Hematopoietic Regulatory Proteins in the differentiation of Myeloid Leukemic Cells
Y. Shabo, J. Latar & L. Sachs

Granulocyte Colony-Stimulating Factor, not Granulocyte-Macrophage Colony-Stimulating Factor, cooperated with Retinoic Acid on the Induction of Functional N-Formylmethionyl-Phenylalanne Receptors on HL-60 Cells
A. Sakashita, T. Nakamacti, N. Tsutuoka, Y. Honma & M. Hozumi

Serum Interleukin-2, Soluble IL-2 Receptors and Tumor Necrosis Factor-Alpha levels are significantly increased in acute Myeloid Leukemia Patients
G. Cimino, S. Amadori, M.C. Cava, V. De Santis, M.C. Iperi, O. Di Gregorio, C. Campari, L. Vegna, G. Cimino & F. Mandelli

Effects of Recombinant Human Granulocyte Colony Stimulating Factor and Granulocyte-Macrophage Colony Stimulating Factor on In Vitro Hemopoeisis in the Myelodyplastic Syndromes
A. Nagler, N. Ginzton, H. Negron, D. Breg, T. Donlon & P. Greenberg

Is the mdr 1 Gene Relevant in Chronic Lymphocytic Leukemia?

Published on behalf of the Sven-Aage Killmann Foundation

Subscription Rates
Monthly
ISSN 0887 6924

ONE YEAR
Institutional £202
Individual £101

TWO YEARS
Institutional £404
Individual £202

The individual rate is only available if you are paying with your personal cheque or credit card.

SEND FOR YOUR FREE SAMPLE COPY

To Dione Stocking, Macmillan Press Ltd, Houndmills, Basingstoke RG21 2XS, UK.

☐ Please send me a FREE sample copy of Leukemia

Name ____________________________

Position ____________________________

Address ____________________________

Postal/Zip Code ____________________________ Country

Onc.
Anti-Cancer Drug Design

An international journal covering an important area of common interest for medicinal chemists, biochemists, biophysicists and oncologists

- Concentrates on the rational scientific principles involved in the development of new anti-cancer agents
- Publishes original research papers which reflect the increasing importance of the tools of structural and molecular biology as well as the more traditional methodologies of pharmacology, chemistry and biophysics
- Publishes both experimental and clinically orientated papers
- Listed in *Index Medicus, Excerpta Medica, BIOSIS, Current Contents* and *Chemical Abstracts*
- Now one of the top twenty most intensively cited primary research oncology journals in the world, as monitored by the latest SCI Journal Citation Reports
- Rapid publication of full papers and communications

**NEW FOR 1991!**

- New American editor, to give added coverage to medicinal chemistry and related areas
- Frequency increased to bi-monthly

---

**Editors**

**Stephen Neidle**
(Institute of Cancer Research, Sutton, UK)
Editor, UK & Rest of World

**Stanley Crooke**
(Pharmaceuticals, California, USA)
Editor, The Americas

**Laurence Hurley**
(University of Texas at Austin, USA)
Editor, The Americas

**Shigeru Tsukagoshi**
(Cancer Chemotherapy Center, Tokyo, Japan)
Editor, Japan

**Editorial Board**

<table>
<thead>
<tr>
<th>F Arcamone, Italy</th>
<th>K R Harrap, UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>K D Bagshawe, UK</td>
<td>S M Hecht, USA</td>
</tr>
<tr>
<td>J R Brown, UK</td>
<td>D W Henry, USA</td>
</tr>
<tr>
<td>A H Calvert, UK</td>
<td>A J Hopfinger, USA</td>
</tr>
<tr>
<td>J S Cohen, USA</td>
<td>M Jarman, UK</td>
</tr>
<tr>
<td>W A Denny, New Zealand</td>
<td>J B LePecq, France</td>
</tr>
<tr>
<td>B W Fox, UK</td>
<td>S J Lippard, USA</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>J W Lown, Canada</td>
<td>D Shugar, Poland</td>
</tr>
<tr>
<td></td>
<td>M G F Stevens, UK</td>
</tr>
<tr>
<td>J A Montgomery, USA</td>
<td>G T Stevenson, UK</td>
</tr>
<tr>
<td>V L Narayanan, USA</td>
<td>G R Pettit, USA</td>
</tr>
<tr>
<td>Y Sakurai, Japan</td>
<td>M J Waring, UK</td>
</tr>
<tr>
<td></td>
<td>P Workman, UK</td>
</tr>
<tr>
<td>A C Sartorelli, USA</td>
<td></td>
</tr>
<tr>
<td>P Schein, USA</td>
<td></td>
</tr>
</tbody>
</table>

---

**Subscription Information**

<table>
<thead>
<tr>
<th>Rate for 2 Years</th>
<th>Rate for 1 Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>EEC</td>
<td></td>
</tr>
<tr>
<td>£220</td>
<td>£110</td>
</tr>
<tr>
<td>Rest of World</td>
<td></td>
</tr>
<tr>
<td>£242</td>
<td>£121</td>
</tr>
<tr>
<td>£280 (airmail)</td>
<td>£145 (airmail)</td>
</tr>
</tbody>
</table>

We welcome payment in your own currency, converted at the current rate.
CALL FOR PAPERS

LUPUS
AN INTERNATIONAL JOURNAL

EDITOR:
Graham R V Hughes
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH England
Tel: +44 71 928 9292 ext 3357 Fax: +44 71 633 9422

ASSOCIATE EDITOR:
Robert G Lahita
Division of Rheumatology & Connective Tissue Diseases
St Luke's Roosevelt Hospital Center,
New York, USA

MANAGING EDITORS:
David Isenberg, London, England
Munther Khamashta, London, England

AIMS AND SCOPE

Research and publications on lupus have both increased rapidly during the past two decades. Not only has worldwide recognition of lupus increased dramatically but the clinical and laboratory observations made on lupus have had implications for diseases in specialties as far removed as obstetrics, nephrology, cardiovascular diseases and psychiatry. Publications on lupus have accordingly been disseminated in a wide variety of journals.

It is felt that an international journal dealing with lupus will have an important place in the bringing together of clinical and laboratory observations. The journal will publish quarterly initially. As well as original papers, it will include editorials and review articles. There will be a correspondence section but case reports will be kept to a very minimum. The journal will cover the increasing number of international conferences on lupus. This interest is gathering momentum with the setting up of the International Conference Series on Lupus, the next of which will be held in London in April 1992.

Frequency: Quarterly
Volume 1: 6 issues
Issue 1: July 1991
Subscription Rate Volume 1: £95

To obtain instructions on preparation of papers, subscribe or reserve a FREE sample copy, return order form to:
Genevieve Eastwood
Scientific and Medical Division
Macmillan Press Ltd
Houndmills, Basingstoke
Hants RG21 2XS, United Kingdom
Tel: +44 256 29242, ext 3168
Fax: +44 256 842754
Our client is a multinational pharmaceutical company with an impressive R&D record and acknowledged leadership in oncology and haematology.

New biotechnology products in these fields are on stream, some exclusive to the company and some in joint-development with other research-based organisations.

The task, dedicated solely to the oncology/haematology franchise, is two-fold. Firstly it is to provide professional advice and support to the principal operating units of the company – clinical research, regulatory affairs, sales and marketing. Secondly it is to manage a large clinical trials programme encompassing phases I-IV.

The need is for a well qualified physician, with full UK GMC registration and with clinical experience at Registrar level or above in oncology and/or haematology.

This is a rare opportunity to participate in leading-edge clinical research with novel compounds in an area of medicine of fast-growing importance to clinicians and to the pharmaceutical industry.

And with this company an international career is a genuine prospect.

If you are appropriately qualified and possess aptitudes for research and management within this industry, please send your cv to Ken Littlechild at Highclere Search Associates or call him for an informal preliminary discussion.
Aims and Scope

The British Journal of Cancer will accept papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

The Journal is published monthly on behalf of the Cancer Research Campaign by the Scientific and Medical Division of Macmillan Press Ltd.

Copyright © 1991 Cancer Research Campaign. ISSN 0007–0920.

Manuscripts plus two copies and all editorial correspondence should be sent to: Dr P.R. Twentyman, Editor, British Journal of Cancer, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.

Telephone: (0223) 210115
Fax: (0223) 213556

All business correspondence and reprint requests should be addressed to the Scientific & Medical Division, Macmillan Press Ltd., Houndmills, Basingstoke, Hampshire RG21 2XS, UK.

Telephone: (0256) 29242
Fax: (0256) 810526

Annual subscription prices: EEC £280, elsewhere £310/US $620 (sterling rate is definitive). Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Press and sent to: Subscription Department, Macmillan Press, Brunel Road, Basingstoke, RG21 2XS, UK.

Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Second class postage permit USPS 689–430.

Postmaster please send address corrections to Mercury Airfreight International Ltd., 2323 E-F Randolph Avenue, Avenel, NJ 07001, USA (US Mailing agent). Second class postage paid at Rahway, NJ.

Enquiries concerning advertising space or rates should be addressed to: Michael Rowley, Advertisement Manager, Macmillan Press Ltd., 4 Little Essex Street, London.

Telephone: 071 836 6633, Fax: 071 379 4204.

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Macmillan Press Ltd for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $3.50 per copy, is paid directly to CCC, 27 Congress St., Salem, MA 01970, USA.

0007–0920/91 $3.50 + $0.00

Cover Illustration. Proteoglycans (PG) have been localised immunohistochemically in a wide range of salivary gland tumours. The upper part of the cover shows an adenoid cystic carcinoma stained for large PG (left), small PG (centre) and chondroitin-6-sulphate PG (right). Individual glycosaminoglycan components of PGs were analysed by HPLC and results are shown in the lower diagram (see paper by Nara et al., this issue p 307).

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and The Fellowship, the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinions or statement. Whilst every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer’s own published literature.

Typeset by Elite Typesetting Techniques, Southampton
Printed in Great Britain by Unwin Brothers Ltd, The Gresham Press, Old Woking, Surrey
Guest Editorial

Alcohol and cancer. An instructive association
Tuyns, A.J.

Are cancer cells acidic?
Griffiths, J.R.

Coagulation and cancer
Murray, C.

The current status of scientific research and hormonal treatments for carcinoma of the prostate
Waxman, J., Saini, A.

Lifestyle and Leukaemia
Cartwright, R.A.

Review

Nucleoside salvage and resistance to antimetabolite anticancer agents
Fox, M., Boyle, J.M., Kinsella, A.R.

Experimental Oncology

Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation
Remvikos, Y., Vieth, P., Padoy, E., Benyahia, B., Voillomot, N., Magdelnat, H.

Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis

Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma d'Uscio, C.H., Jungi, T.W., Blaser, K.

31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance

Human tumour-associated NK cells secrete increased amounts of interferon-γ and interleukin-4
Lorenzen, J., Lewis, C.E., Mc Cracken, D., Horak, E., Greenall, M., McGee, J.O.D.

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens
Kosmas, C., Epenetos, A.A., Courtenay-Lack, N.S.

Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis
Russo, J.H., Koszalka, M., Russo, J.

Flow cytometric DNA measurement and cytomorphometric analysis of formalin fixed rat mammary tumours

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line
Cito, G., cucco, C., Verdua, A., Zupi, G.

Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein
Hunter, J., Hirst, B.H., Simmons, N.L.

A prolatin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy
Wijman, J.H., Cornelisse, C.J., Keijzer, R., van de Velder, C.J.H., van Dienendonck, J.H.

Whole body hyperthermia and carboplatin: cytotoxicity for murine leukaemia and normal marrow
Tapazoglu, E., Cohen J.D., Schmit, C.L., Khataha, A., Sapareto, S.A., Robins, H.I.

Distribution of photofrin between tumour cells and tumour associated macrophages
Korbelik, M., Krosl, G., Olive, P.L., Chaplin, D.J.

Enhancement of pulmonary tumour seeding by human coagulation factors II, IX, X—an investigation into the possible mechanisms involved
Paruthotham, A., McCulloch, P., George, W.D.

Effects of cycloheximide on 3H-chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis
Colling, R.J., Harman, B.V., Soulios, T., Pope, J.H., Kerr, J.F.R.

In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood

c-src structure in human cancer with elevated pp60c-src activity
Wang, P., Fromowitz, F., Koslow, M., Hugag, N., Johnson, B., Viola, M.

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer
Macaudal, J.V.M., Smith, I.E., Everard, M.J., Teale, J.D., Reubi, J.-C., Millar, J.L.

Clinical Oncology/Epidemiology

Histological features, DNA content and prognosis of breast carcinoma found incidentally or in screening
Joensuu, H., Toikkanen, S., Klemi, P.J.

Epidemiology evidence for age-dependent regression of pre-invasive cervical cancer
von Portmarssen, G.J., Habema, J.D.F.

Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86)–how much treatment is needed?
Pinkerton, C.R., Haun, I., Eden, O.B., Gerrard, M., Berry, J., Mott, G.G.

The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk
Keefe, M., MacKie, R.M.

An assessment of combined tumour markers in patients with seminoma: placental alkaline phosphatase (PLAP), lactate dehydrogenase (LD) and β human chorionic gonadotrophin (ßHCG)
Muro, A.J., Nielsen, O.S., Duncan, W., Sturgeon, J., Gospodarowicz, M.K., Malink, A., Thomas, O.M., Jewett, M.A.S.

Death due to recurrence following curative resection of early gastric cancer depends on age of the patient
Moriguichi, S., Odaka, T., Hayashi, Y., Nose, Y., Maehara, Y., Korenaga, D., Sugimachi, K.

Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy
Visakorpi, T., Kalilioniemi, O.-P., Paronen, I.Y.I., Isola, J., Heikkinen, A.I., Koivula, T.A.

A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer
Mane, J.L., de Graeff, A., Newell, D.R., Glaholm, J., Button, D., Leach, M.O., Payne, G., Smith, I.E.

Childhood cancer and ethnic group in Britain: a United Kingdom Children's Cancer Study Group (UKCCSG) Study Stiller, C.A., McKinney, P.A., Bunch, R.J., Bailey, C.C., Lewis, I.J.

Compliance with follow-up patients treated for non-seminomatous testicular cancer
Young, B.J., Bultz, B.D., Russell, J.A., Trew, M.S.

Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck
Field, J.K., Spandidos, D.A., Malitiri, A., Gosney, J.R., Yiagnisti, M., Stell, P.M.
A randomised trial of planned vs as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

Contacts between adults as evidence for an infective origin of childhood leukaemia: an explanation for the excess near nuclear establishments in West Berkshire?
Kinden, L.J., Hudson, C.M., Stiller, C.A.

A less toxic regime of 5-fluorouracil and high-dose folic acid for advanced gastrointestinal adenocarcinomas
Johnson, P.W.M., Thompson, P.J., Seymour, M.T., Deasy, N.P., Thuraiingham, R.C., Slevin, M.L., Wrigley, P.F.M.

Correspondence
Season of detection of breast cancer (cont)
Mason, B., Holdaway, I.

Editorial Announcement

This issue of the British Journal of Cancer contains a revised version of the 'Notice to Contributors'.

The changes from the previous version are mainly clarifications of existing instructions. The format for 'Short Communications' has however been substantially revised. We now ask that such papers contain the usual section headings plus a short summary of around 50 words. This will make it possible for summaries to be included in computer databases.

There are two changes in the format for references. We now require that the names of all authors are given in the reference list, even when there are more than 6 authors. In addition, the first and last page numbers of all referenced papers and book chapters are to be given.

In accordance with the practise of almost all other biomedical journals we now find it necessary to charge authors for all colour illustrations and this is now pointed out in the 'Notice to Contributors'.
Notice to Contributors

The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission. The Editors reserve the right to make literary corrections.

Papers reporting clinical studies should, where appropriate, contain a statement that they have been carried out with ethical committee approval. Single case studies are not usually acceptable. Papers disregarding the welfare of experimental animals will be rejected. Authors may find the UKCCCR 'Guidelines for the Welfare of Animals in Experimental Neoplasia' helpful in this regard. These were published in the British Journal of Cancer (1988) 58, pp. 109–113. Alternatively, copies may be obtained from: UKCCCR, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK.

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr Peter Twyman. They should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors' full names, affiliation and complete addresses, including postal (zip) codes; and a summary of not more than 200 words. The author and address to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

A series of Editorials explaining the editorial policies and practices of the British Journal of Cancer was published in the Journal between November 1990 and March 1991. Composite reprints of these articles are available from the Editor on request.

Full papers should be divided into sections: 1. Introduction 2. Materials and methods 3. Results 4. Discussion 5. Acknowledgements and References.

Short Communications (~1500 words) should have the above section headings and a brief summary (~50 words).

Titles These are most important; authors should compose theirs with care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters.

References Only papers closely related to the author's work should be quoted, and these should where possible be original papers rather than reviews. Exhaustive lists should be avoided. Citation of Conference Proceeding or Meeting Abstracts should also be avoided unless there is no other reference. References in the text should be made by giving the author's surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc, should be added after the year of publication. It is the author's responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors' names should be given in full. Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors' initials), followed by the volume numbers and the initial and final page numbers, e.g.:


References to books and monographs should appear as in the following examples:


Abbreviations and units should follow the standards laid down in Units Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Figures In the text Arabic numbers should be used and all illustrations should be specifically referred to in the text, e.g. (Figure 2). All illustrations should be submitted at about 1½ times the intended final size and should be numbered as figures whether they are photographs, representational drawings or line diagrams and graphs. Copies of all Figures must accompany each of the 3 submitted copies of the manuscript. Photographs and photomicrographs should be unmounted glossy prints, should not be retouched, and should be chosen to exclude technical artefacts. Magnification should be indicated by a line representing a defined length included within the photograph. Areas of key interest and/or critical reproduction should be indicated on a flimsy overlay attached to the photograph or on a photocopy. All annotation and lettering should be indicated in the same way, and preferably not included on the original print. Clearly contrasted and focussed prints are essential for adequate reproduction. Three originals of all photographs must be submitted. Photocopies of half-tone illustrations are generally unsuitable for refereeing purposes.

Full colour illustrations may be included within the text, at the discretion of the Editor. However, a charge will be made to the author to cover the extra costs incurred in originating and printing of colour illustrations. Authors will be advised of any such charges, which depend on the size and quantity of colour illustrations, prior to publication.

Line diagrams and graphs should be on separate sheets; they must be drawn with black ink on white paper or represent computer-generated output printed using laser or ink jet printers with appropriate line-smoothing facilities. Lettering on figures should be such that it will be discernible when the photograph is reduced to the final legible size. The use of symbols should be consistent within papers, and explanation of symbols should be included in the caption, not on the figure. Symbols should be sufficiently large that they will be clearly discernible following reduction.

Tables These should be as few as possible and should present only essential data. They should be typewritten on separate sheets, have a title or caption, and given Roman numbers.

Proofs Two marked copies of the proofs will be sent to the principal author and should be read carefully for errors. One corrected copy must be returned to the Editor within 3 days. Major alterations to the text cannot be accepted.

Copyright Assignment The principal author must complete and return to the Publisher the Copyright Assignment Form enclosed with the proofs.

Offprints Twenty-five offprints will be supplied free of charge to the principal author. Additional offprints may be ordered on the form accompanying proofs. The charges are necessarily higher if orders are received after the issue has gone to press.

*Editorial correspondence (other than in direct response to a communication from the Clinical Editor) should be addressed to Dr P.R. Twyman, Editor, British Journal of Cancer, MRC Clinical Oncology and Radiotherapies Unit, Hills Road, Cambridge CB2 2QH, UK.